Hit enter to search or ESC to close

Investor Centre

Alterity Therapeutics is developing best-in-class therapies to treat neurodegenerative disease.

The Company was incorporated in 1997 in Melbourne, Australia and listed on the Australian Securities Exchange in 2000 and NASDAQ in 2002 as Prana Biotechnology. It changed its name by Shareholder Approval on 5th April 2019.

The company operates under the tickers ASX: ATH and NASDAQ: ATHE.

ASX

  • Loading stock data...

NASDAQ

  • Loading stock data...

Investment Highlights

  • Well-funded clinical stage drug development company following up to $44M strategic investment led by Life Biosciences LLC allowing accelerated and focused clinical development.
  • Strong and highly experienced board and management team with significant R&D and commercialisation experience including 3 drug approvals by US FDA.
  • PBT434 is a novel drug candidate targeting key proteins implicated in neurodegeneration of Parkinson’s disease and atypical parkinsonism.
  • PBT434 is completing its Phase 1 clinical trial program.
  • First therapeutic target selected – Multiple System Atrophy (MSA), a form of atypical parkinsonism, is a devastating disease with no approved treatments.
  • FDA Orphan Drug designation for PBT434 for the treatment of MSA received.
  • Significant market potential for MSA alone – estimated peak sales of US$750M.

Investor Resources

Investor presentations

ASX Announcements

2019

2018

Financial reports

2019

2018

Corporate governance

News

Quarterly Cash Flow Report

Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve concentrations

Read More
Quarterly Cash Flow Report

Highlights: Results of Phase 1 Clinical Trials for lead compound PBT434 announced Presentation of clinical trial data at the 2019 Internatio

Read More

Receive news from Alterity Therapeutics